Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE AUTOINJECTOR versus ATROPINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE AUTOINJECTOR versus ATROPINE SULFATE.
ATROPINE (AUTOINJECTOR) vs ATROPINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine at parasympathetic postganglionic junctions. Increases heart rate, reduces exocrine secretions, relaxes smooth muscle in GI and GU tracts, and dilates pupils.
2 to 4 mg intramuscularly (lateral thigh) or intravenously, repeated every 10-20 minutes if needed until muscarinic signs abate, maximum 3 doses.
0.5 to 1 mg intravenously or intramuscularly every 3 to 5 minutes as needed, up to a total of 3 mg (3 doses) for bradycardia; 0.5 to 1 mg subcutaneously, intramuscularly, or intravenously every 4 to 6 hours for antisecretory effects; 1 to 2 mg intravenously every 5 minutes for organophosphate poisoning.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (adults); prolonged to 6-12 hours in elderly or hepatic impairment.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged in elderly and infants; clinically significant due to potential accumulation with repeated dosing.
Renal: ~30-50% unchanged; hepatic metabolism: ~50%; fecal: minor.
Renal excretion of unchanged drug and metabolites; ~50% excreted unchanged in urine; remainder as inactive metabolites (tropine, tropic acid); biliary/fecal excretion minor.
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent